Pulse Biosciences Inc
PLSE
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.72B
Close$
$1.08
97.6% downside
Current Fair Value
97.6% downsideOvervalued by 97.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.72 Billion |
|---|---|
| Enterprise Value | $3.63 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.08 |
| Beta | 1.57 |
| Outstanding Shares | 69,200,020 |
Return
| Return on Equity | -80.46% |
|---|---|
| Return on Assets | -69.27% |
| Return on Invested Capital | -78.27% |
Valuation & Multiples
| P/E Ratio | -45.99 |
|---|---|
| PEG | -160.61 |
| Price to Sales | - |
| Price to Book Ratio | 45.59 |
| Enterprise Value to Revenue | 4845.56 |
| Enterprise Value to EBIT | -44.34 |
| Enterprise Value to Net Income | -46 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.31
Average shareholder expectationRevenue Estimate
$533,333
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-0.35
Average shareholder expectationRevenue Estimate
$520,833
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 30.47% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.01%▼ 15.69% |
|---|---|
| Total Invested | $412,789▼ 99.86% |
| Investors Holding | 4▼ 108.00% |
ESG Score
No data
About Pulse Biosciences Inc
95 employeesPulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The CellFX® System is the first commercial product to harness the distinctive ad...